NIH Small Business Grants: SBIR and STTR Programs
The National Institutes of Health administers two federally mandated programs — the Small Business Innovation Research (SBIR) program and the Small Business Technology Transfer (STTR) program — that direct a portion of NIH's extramural research budget toward commercially oriented innovation. These programs fund early-stage biomedical and behavioral research conducted by small businesses, bridging the gap between laboratory discovery and marketable health technologies. Understanding the structure, eligibility rules, and phase distinctions of each program is essential for founders, researchers, and technology transfer offices navigating NIH funding. For a broader orientation to NIH funding instruments, the NIH Authority home page provides an overview of the agency's scope and structure.
Definition and Scope
SBIR and STTR are Congressional mandates, not discretionary programs. The Small Business Innovation Research program was established under the Small Business Innovation Development Act of 1982 and is reauthorized periodically by Congress through the Small Business Administration (SBA SBIR/STTR Policy Directive). Federal agencies with extramural research budgets exceeding $100 million annually are required by statute to set aside a percentage of those budgets for SBIR awards (15 U.S.C. § 638). NIH, as the largest civilian biomedical research funder in the United States with a fiscal year 2023 budget exceeding $47 billion (NIH Budget and Funding), is among the heaviest participants in both programs.
The SBIR set-aside rate is 3.2% of an agency's extramural research budget (as of the 2022 reauthorization), while the STTR set-aside is 0.45% (SBA Policy Directive, October 2022).
Both programs require awardees to be:
STTR adds a mandatory formal collaboration requirement with a U.S. research institution — a university, federally funded research and development center (FFRDC), or nonprofit research organization — that does not apply under SBIR.
How It Works
Both programs use a three-phase structure:
-
Phase I — Feasibility assessment. Awards are capped by NIH at approximately $150,000–$300,000 for a period of up to 6 months (SBIR) or 1 year (STTR). The purpose is to establish the technical merit and scientific feasibility of the proposed concept.
-
Phase II — Full R&D. Awards typically reach $1,000,000–$2,000,000 over 2 years. Only Phase I awardees are generally eligible to apply for Phase II. The work plan must demonstrate a credible path to commercialization.
-
Phase III — Commercialization. No SBIR/STTR funds are awarded at this stage. The company pursues private investment, non-SBIR federal contracts, or other non-set-aside federal funding to bring the product or technology to market.
NIH also operates a Fast-Track mechanism that combines Phase I and Phase II into a single application, reducing transition delays for applicants with strong feasibility data.
Principal investigators on SBIR applications must have their primary employment (more than 50% effort) at the small business concern at the time of award. This is a key eligibility constraint that distinguishes SBIR from standard NIH research project grants. Details on standard grant types are covered in NIH Grant Types and Mechanisms.
Applications proceed through the standard NIH peer review system, which evaluates significance, investigators, innovation, approach, and environment — the same five criteria applied to R01 and other investigator-initiated mechanisms. The NIH Peer Review Process page describes those criteria in depth.
Common Scenarios
Biotech startup seeking proof-of-concept funding: A company with a novel diagnostic assay applies for an SBIR Phase I award through the National Cancer Institute. The PI holds a faculty appointment but restructures employment to meet the 51% effort requirement at the company before award activation.
University spinout with IP licensing: A lab at a research university licenses a therapeutic compound to a newly incorporated small business. The business applies under STTR, designating the university as the required collaborating institution. Under STTR rules, at least 30% of the funded work must be performed by the small business and at least 30% by the partnering research institution (SBA Policy Directive, §4).
Phase II to Phase III bridge: After a successful Phase II award, a medical device company has not yet secured private investment. NIH's Commercialization Assistance Program and the National Cancer Institute's NCI SBIR Development Center provide non-dilutive technical assistance to prepare the company for Series A financing — neither constituting Phase III funding itself.
Decision Boundaries
The primary decision for an applicant is whether to apply under SBIR or STTR. The comparison below identifies the operative differences:
| Criterion | SBIR | STTR |
|---|---|---|
| Research institution collaboration | Not required | Mandatory |
| PI employment requirement | >50% at small business | No primary employment requirement |
| Small business work performance | At least 67% of Phase I work | At least 30% of funded work |
| Research institution work share | No minimum | At least 30% |
| IP ownership default | Small business | Negotiated between business and institution |
Applicants with strong academic collaborators and PI investigators who retain university appointments typically select STTR. Applicants whose core team resides within the company and who do not require institutional infrastructure generally select SBIR.
NIH's NIH Grant Application Process page details submission requirements, due dates, and the electronic submission pathway through Grants.gov and the eRA Commons system. Awarded SBIR and STTR projects are indexed and publicly searchable in the NIH RePORTER Database.